Literature DB >> 10386176

The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder.

C L Bowden1, J R Calabrese, S L McElroy, L J Rhodes, P E Keck, J Cookson, J Anderson, C Bolden-Watson, J Ascher, E Monaghan, J Zhou.   

Abstract

BACKGROUND: Patients with bipolar disorder (BD) who have rapid cycling features are often treatment refractory. Clear and conclusive evidence regarding effective treatments for this group is not available.
METHODS: Patients with diagnoses of refractory bipolar disorder who were currently experiencing manic, mixed, depressive, or hypomanic episodes were treated with lamotrigine as add-on therapy (60 patients) or monotherapy (15 patients). We compared the efficacy of lamotrigine in the 41 rapid cycling and 34 non-rapid cycling patients with BD.
RESULTS: Improvement from baseline to last visit was significant among both rapid cycling and non-rapid cycling patients for both depressive and manic symptomatology. For patients entering the study in a depressive episode, improvement in depressive symptomatology was equivalent in the two groups. Among patients entering the study in a manic, mixed, or hypomanic episode, those with rapid cycling improved less in manic symptomatology than did non-rapid cycling patients. Among rapid cycling patients with initial mild-to-moderate manic symptom severity, improvement was comparable to that in non-rapid cycling subjects; however, the subset of rapid cycling patients with severe initial manic symptomatology had little improvement in mania. Rapid cycling patients had earlier onset and more lifetime episodes of mania, depression, and mixed mania.
CONCLUSIONS: Lamotrigine was generally effective and well tolerated in this group of previously non-responsive, rapid cycling bipolar patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386176     DOI: 10.1016/s0006-3223(99)00013-x

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  23 in total

1.  Psychiatric Uses of Newer Anticonvulsants.

Authors:  Timothy R. Berigan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-04

Review 2.  Emerging options in the treatment of bipolar disorders.

Authors:  M Berk; J Segal; L Janet; M Vorster
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Comparison of treatment outcome using two definitions of rapid cycling in subjects with bipolar II disorder.

Authors:  Jay D Amsterdam; Lorenzo Lorenzo-Luaces; Robert J DeRubeis
Journal:  Bipolar Disord       Date:  2017-02-03       Impact factor: 6.744

Review 4.  The use of newer anticonvulsants in neuropsychiatric disorders.

Authors:  Edward Kim
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

Review 5.  HCN Channel Targets for Novel Antidepressant Treatment.

Authors:  Stacy M Ku; Ming-Hu Han
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

6.  Symptoms of epilepsy and organic brain dysfunctions in patients with acute, brief depression combined with other fluctuating psychiatric symptoms: a controlled study from an acute psychiatric department.

Authors:  Arne E Vaaler; Gunnar Morken; Olav M Linaker; Trond Sand; Kjell A Kvistad; Geir Bråthen
Journal:  BMC Psychiatry       Date:  2009-09-30       Impact factor: 3.630

Review 7.  Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection.

Authors:  Xiaohua Li; Gautam N Bijur; Richard S Jope
Journal:  Bipolar Disord       Date:  2002-04       Impact factor: 6.744

Review 8.  Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy.

Authors:  Kathryn J Macdonald; L Trevor Young
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 9.  Safety and tolerability of lamotrigine for bipolar disorder.

Authors:  Charles L Bowden; Gregory M Asnis; Lawrence D Ginsberg; Beth Bentley; Robert Leadbetter; Robin White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk.

Authors:  L Lorenzo-Luaces; J D Amsterdam; I Soeller; R J DeRubeis
Journal:  Acta Psychiatr Scand       Date:  2016-01-24       Impact factor: 6.392

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.